Drug delivery technology developer Cure Pharmaceutical (OTC:CURR) announced today that it launched two new clinical development programs. Oxnard, Calif.-based Cure’s first new launch is an antiviral clinical development program for loading a known active pharmaceutical ingredient (API) onto its Curefilm patented drug delivery platform that optimizes the absorption and metabolism of therapeutic devices, according to […]
Eitan Medical wins EU clearance for Sapphire infusion pump
Eitan Medical announced that it received European Union Medical Device Recognition (MDR) certification for its Sapphire infusion pump. Approval for the Sapphire infusion pump, along with its accessories and administration sets, was granted in January 2021, according to a news release. The certification is EU MDR 2017/45. Sapphire includes upgraded Rev15 software, also EU MDR […]
Soleo Health to administer Givlaari injections
Soleo Health announced that it joined the treatment center directory for Givlaari and can now administer it for adults with AHP. Givlaari, managed by Alnylam Pharmaceuticals (NSDQ:ALNY), is the first FDA-approved treatment for acute hepatic porphyria (AHP) in adults. The once-monthly injection for subcutaneous use reduces the levels of neurotoxins associated with AHP attacks and […]
NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19
NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]
PerkinElmer completes Oxford Immunotec acquisition
PerkinElmer (NYSE:PKI) announced today that it completed its previously announced acquisition of Oxford Immunotec. Under the acquisition agreement announced in January, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 million. […]
Jabil, E3D team up on auto-injector development
Jabil (NYSE:JBL) division Jabil Healthcare announced a collaboration agreement with E3D, giving it access to E3D’s auto-injector. The agreement with the global drug delivery device company, which is a member of the Elcam Medical Group, gives Jabil exclusive rights to develop a high-volume reusable autoinjector and connected variants, according to a news release. St. Petersburg, […]
Intersect ENT posts mixed bag Q4
Intersect ENT (NSDQ:XENT) posted a mixed bag of results for the fourth quarter, topping consensus revenue estimates but missing on earnings. The Menlo Park, Calif.-based company posted losses of –$20.2 million, or –62¢ per share, on sales of $28.2 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of […]
DarioHealth ticks up before market opens on Q4 results
DarioHealth (NSDQ:DRIO) shares ticked up in pre-market trading today on fourth-quarter revenues that equaled the consensus forecast. The New York–based digital therapeutics company posted losses of –$9 million for the three months ended Dec. 31, 2020, representing a more than doubled bottom-line slide from the same quarter last year on sales growth of 15.7%. The […]
PainReform rasies $6M in private placement
PainReform (NSDQ:PRFX) announced today that it entered into securities purchase agreements to raise approximately $6 million. Herzliya, Israel-based PainReform entered into the agreements with certain institutional investors to raise the $6 million through the private placement of more than 1.3 million ordinary shares and accompanying warrants to purchase up to 652,173 ordinary shares at a […]
FDA grants orphan drug designation for Steba Biotech’s urothelial cancer drug
Steba Biotech announced today that it received FDA orphan drug designation (ODD) for its Padeliporfin ImPACT for treating UTUC. Padeliporfin ImPACT (immune photo-activated cancer therapy) is designed to offer surgery-like efficacy combined with organ preservation through the intravenous delivery of an inactive drug, according to a news release. Once activated, the drug rapidly triggers the […]
